Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-19

Shama Ahmad, Shajer Manzoor, Simmone Siddiqui, Nithya Mariappan, Iram Zafar, Aamir Ahmad, Aftab Ahmad *

Division of Molecular and Translational Biomedicine, Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

ARTICLE INFO

Keywords:
Inflammation
Epigenetics
COPD
ARDS
Lung cancer
COVID-19

ABSTRACT

Inflammation is an essential component of several respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and acute respiratory distress syndrome (ARDS). It is central to lung cancer, the leading cancer in terms of associated mortality that has affected millions of individuals worldwide. Inflammation and pulmonary manifestations are also the major causes of COVID-19 related deaths. Acute hyperinflammation plays an important role in the COVID-19 disease progression and severity, and development of protective immunity against the virus is greatly sought. Further, the severity of COVID-19 is greatly enhanced in lung cancer patients, probably due to the genes such as ACE2, TMPRSS2, PAI-1 and furin that are commonly involved in cancer progression as well as SAR-CoV-2 infection. The importance of inflammation in pulmonary manifestations, cancer and COVID-19 calls for a closer look at the underlying processes, particularly the associated increase in IL-6 and other cytokines, the dysregulation of immune cells and the coagulation pathway. Towards this end, several reports have identified epigenetic regulation of inflammation at different levels. Expression of several key inflammation-related cytokines, chemokines and other genes is affected by methylation and acetylation while non-coding RNAs, including microRNAs as well as long non-coding RNAs, also affect the overall inflammatory responses. Select miRNAs can regulate inflammation in COVID-19 infection, lung cancer as well as other inflammatory lung diseases, and can serve as epigenetic links that can be therapeutically targeted. Furthermore, epigenetic changes also mediate the environmental factors-induced inflammation. Therefore, a better understanding of epigenetic regulation of inflammation can potentially help develop novel strategies to prevent, diagnose and treat chronic pulmonary diseases, lung cancer and COVID-19.

1. Introduction

Humans are exposed to numerous infections, toxins, irritants etc. on a daily basis and inflammation is one of the ways by which a body fights them off through the involvement of immune cells, vascular system as well as other molecular mediators. The process of inflammation essentially comprises eliminating the ‘trigger’, minimizing damage, clearing of damaged cells/tissues and initiation of repair mechanisms [1]. Inflammation can either be rapid and short-lived (acute) or maybe recurring and slow and last for prolonged durations (chronic) [2], and the two subtypes markedly differ in the way different cells are mobilized, with acute inflammation involving granulocytes and the chronic inflammation involving agranulocytes. Acute inflammation can cause lung injury leading to acute respiratory distress syndrome (ARDS). Chronic inflammation can lead to (or persists in) several chronic diseases such as cancer, heart diseases, diabetes, asthma, chronic obstructive pulmonary disease (COPD), arthritis and Alzheimer’s. Thus, inflammation is an important feature that affects the cells and organ systems, and plays a critical role in both acute and chronic disease pathogenesis. Persistence of inflammation can exacerbate secondary insults and also increase susceptibilities to injuries and infections caused by microorganisms (bacteria and viruses like SARS-CoV-2).

Among the many chronic diseases linked to inflammation are several pulmonary diseases and lung cancer. Diseases such as asthma, COPD and pulmonary fibrosis are well known to be the result of persistent inflammatory processes [3]. Likewise, the role of inflammation in cancer
Inflammation connects COVID-19 and cancer with pulmonary diseases. 

**2. Inflammation as underlying cause of pulmonary diseases**

Uncontrolled inflammation is a major component of many pulmonary diseases, such as COPD, ARDS and idiopathic pulmonary fibrosis (IPF), all of which are linked to high mortality and/or morbidity rates [14–16]. Pulmonary inflammation is a hallmark of many acute and chronic pathophysiological inflammatory processes and there is considerable experimental and clinical evidence that pro-inflammatory cytokines, chemokines as well as adhesion molecules play a major role in its pathogenesis. The inflammatory response is complex and involves a variety of mechanisms to defend against pathogens and abnormal tissue repair [17]. In the lung, inflammation can be caused by pathogens or by exposure to toxins, pollutants, irritants, and allergens [18–20]. Pulmonary insults trigger a complex host response, involving an interplay of pro- and anti-inflammatory factors leading to tissue repair or organ injury and secondary pathophysiological changes [18]. Each insult triggers the release of cytokines and mediators that modify inflammatory responses in a unique way. Activation and recruitment of inflammatory cells, such as macrophages, lymphocytes, neutrophils, and eosinophils, serves as the source of different kinds of inflammatory mediators such as histamine, TNF-α, interleukins (IL-1β, IL-4, IL-5 and IL-6), prostaglandins, leukotrienes, and DAMPs (Damage Associated Molecular Patterns) that are necessary for the onset of pulmonary inflammation. The release of these inflammatory mediators correlates with the characteristics of pulmonary disease such as loss of lung function, airway hyperresponsiveness and obstruction, edema, mucus hypersecretion and lung remodeling [16].

ARDS, a chronic inflammatory disease, often manifests as the combination of emphysema and chronic obstructive bronchitis, where emphysema is due to breakdown of the alveoli and the chronic obstructive bronchitis is a result of chronic inflammation of bronchial tubes. In patients with COPD, there is a characteristic pattern of inflammation with increased numbers of neutrophils in the airway lumen along with increased numbers of macrophages, T lymphocytes, and B lymphocytes [17,21]. Such inflammatory response involves both innate and adaptive mechanisms [22]. Proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6, are found in increased amounts in the sputum and BALF of individuals with asthma and COPD. This is due to an amplified inflammatory response, in part through the activation of NF-κB, which leads to the increased expression of multiple inflammatory genes.

Asthma is another chronic inflammatory lung disease of the airways. Asthma involves inflammation of bronchial tubes resulting in narrower air passages and difficulty in breathing, whereas COPD involves both airways and the lung [3]. Patients with severe asthma have airway inflammation that resembles COPD, suggesting a convergence of cytokine networks [23,24]. Although over 50 cytokines have been implicated in the onset of asthma, their role in the exact pathophysiology of the disease is still poorly understood. Environmental factors are frequently associated with asthma. Given the known role of environmental factors in modulating epigenetic changes, it is conceivable that epigenetic regulation of inflammatory genes plays a critical role in the pathophysiology of this disease [25].

Acute effects of overactivated inflammation are often manifested in lung injury leading to ARDS, a devastating form of respiratory failure. Over the past several years, there have been significant advances in our understanding of ARDS pathogenesis. The risk factors leading to ARDS can be either due to direct insult to the lung like in pneumonia (bacterial, viral, fungal), inhalation injury and aspiration of gastric contents, or indirect like in sepsis, burn, and trauma, where insult to the lungs is caused by various systemic inflammatory mediators. In addition, inflammatory cell migration, fibro-proliferation and apoptosis also play important roles in the pathophysiology of ARDS [26,27]. ARDS is characterized by rapid onset of widespread inflammation in the lungs [28] with injury to the alveolar capillary barrier and extravasation of protein-rich edema fluid into the airspace [29–31]. The degree of alveolar epithelial injury is the major prognostic marker of ARDS. Specifically, in ARDS, pulmonary edema fluid contains high levels of pro-inflammatory cytokines including IL-1β, IL-8, IL-6, TNFα, and transforming growth factor-β1 (TGFβ1) [32]. When excessive levels of cytokines are present, they cause alveolar injury [33–35]. The accumulated fluid in the interstitial and air spaces of the lungs also leads to difficulty in breathing and impaired gas exchange, resulting in hypoxemia and reduced carbon dioxide excretion, which often leads to acute respiratory failure [36]. Moreover, many cell types are involved in the pathophysiology of ARDS including platelets, neutrophils, alveolar macrophages, and monocytes, as well as endothelial and alveolar epithelial cells. Microbial products or cell-injury associated endogenous molecules like DAMPs, bind to Toll-like receptors on the lung epithelium and alveolar macrophages and activate the innate immune system [37]. Mechanisms of innate immune defense, such as the formation of neutrophil extracellular traps (NETs) and histone release, can be beneficial in capturing pathogens, but may also worsen alveolar injury [38]. The immune system also generates reactive oxygen species (ROS), leukocyte proteases, chemokines, and cytokines that help neutralize pathogens, but can also adversely affect the lungs [39]. Thus, the pathophysiology of various pulmonary diseases is intricately connected with the characteristics of pulmonary disease such as loss of lung function, airway hyperresponsiveness and obstruction, edema, mucus hypersecretion and lung remodeling [16].

Fig. 1. Inflammation connects COVID-19 and cancer with pulmonary diseases. In addition to genetic predisposition, several extrinsic factors such as, bacterial / viral infections and environmental agents can cause inflammation, with an emerging realization for the involvement of epigenetic regulation. Inflammation leads to pulmonary manifestations exemplified by ARDS and COPD, which are observed in COVID-19 as well as lung cancer patients.
with systemic inflammation and the related aberrant immune responses.

3. Pulmonary manifestations of COVID-19

No other disease has affected the global human population the way COVID-19 has. The primary target of SARS-CoV-2 infection is the respiratory tract. The nasal passage and cavity is the first to get infected and then the virus is aspirated down the trachea, bronchi and the lungs [40, 41]. SARS-CoV-2 primarily utilizes the ACE2 receptor on host cell for entry. It has been proposed that ACE2 is present at low levels in the ciliated epithelial cells of the airways allowing viral entry and the antiviral response (by the host cell) to induce an increase in ACE2 expression, furthering the spread of SARS-CoV-2 infection into the respiratory mucosa and the lung alveolar epithelial cells [42,43]. It is however interesting that ACE2 expressing club cells were not found to be infected by SARS-CoV-2 [40]. Although, autopsy samples of patients that died of COVID-19 demonstrate virus positivity in these regions of the airways and lung, it is unclear as to how the viral infection causes less severe or very little effect in asymptomatic patients. Patients with severe COVID-19 progress to pneumonia, ARDS and even sepsis. The disease severity is greater in patients with existing lung diseases such as COPD. The weakened immune system may also cause superinfection with secondary bacteria or virus. Thus, survivors of a serious case of COVID-19 will have a challenging recovery as the lungs may get scarred and the lung function severely compromised.

3.1. Lung inflammation in COVID-19

Our knowledge on COVID-19 is rapidly evolving but there is a clear connection between inflammation and onset as well as progression of the disease [44]. Even in children and adolescents, the so called ‘low-risk’ categories for COVID-19, inflammation-associated aggressive form of COVID-19 has been reported [45]. Clinical resolution of inflammation can possibly impact the survival of COVID-19 patients [46]. Several studies have indicated that SARS-CoV-2 causes injury predominantly through host immune dysregulation, increase in inflammation and/or hyperinflammation leading to severity of the disease, resulting in high rate of hospitalizations and mortality. The severity of infection often depends on the intricate balance between host innate and adaptive immune response.

The SARS-CoV-2 virus enters the host cells through angiotensin-converting enzyme 2 (ACE2) binding and internalization. Loss of ACE2 function results in activation of angiotensin type 1 receptor (ATIR) hyperinflammation leading to severity of the disease, resulting in high chances for COVID-19 patients to die [44]. Even in children and adolescents, the so called ‘low-risk’ categories for COVID-19, inflammation-associated aggressive form of COVID-19 has been reported [45]. Clinical resolution of inflammation can possibly impact the survival of COVID-19 patients [46]. Several studies have indicated that SARS-CoV-2 causes injury predominantly through host immune dysregulation, increase in inflammation and/or hyperinflammation leading to severity of the disease, resulting in high rate of hospitalizations and mortality. The severity of infection often depends on the intricate balance between host innate and adaptive immune response.

The SARS-CoV-2 virus enters the host cells through angiotensin-converting enzyme 2 (ACE2) binding and internalization. Loss of ACE2 function results in activation of angiotensin type 1 receptor (ATIR) and Mas receptor (MasR) along with MAPK and ERK pathways, finally resulting in the release of inflammatory mediators such as TGF-β, IL-6, MIP1α, IP10 and TNF-α. It was recently demonstrated that in severe COVID-19, SARS-CoV-2 infection augmented the release of proinflammatory cytokines and chemokines that resulted in the death of host monocyte-derived macrophages and dendritic cells [47]. Moreover, the virus processing in the host cells also results in the release of damage associated molecular patterns (DAMPs). All these events further activate the adaptive immune response leading to systemic cytokine storm and hyperinflammation and severity of infection causing multi organ injury. Targeting therapeutics against these cytokine mediators, complement systems as well as ACE2 upregulation can potentially attenuate the injury and reduce mortality [48,49]. Based on emerging evidence, it is clear that the process of inflammation is intricately involved in the SARS-CoV-2-mediated complications and a more detailed knowledge of the underlying processes can possibly help mitigate the disease.

The spectrum of lung disease from SARS-CoV-2 infection varies from lack of symptoms to mild pneumonia to severe disease associated hypoxemia, respiratory and multiorgan failure and death. Hypoxemia, unlike those of ARDS, is another atypical early disease feature of COVID-19 often referred to as “happy hypoxia” or “silent hypoxia” as it is hidden and well tolerated [50]. SARS-CoV-2-induced inflammation of the respiratory centers has been proposed as one of the causes of silent hypoxia and subsequent respiratory failure [50,51]. ARDS is the most common manifestation of severe COVID-19 disease. SARS-CoV-2 infection of the lungs causes diffuse alveolar damage, apoptotic epithelial cells, interstitial inflammation, and activated T-cell responses resulting in a cytokine storm [51]. Macrophage infiltration, hyaline membrane formation, alveolar edema, and septal thickening is also observed. These features are mostly observed in the autopsies. A number of studies have been conducted to reveal the pathology of the disease [52–54]. In an elegant study, Ackermann et al. compared the lungs of patients who died of COVID-19 with the lungs of patient who died from H1N1 influenza [55]. Besides the common ARDS like features such as diffuse alveolar damage and perivascular T-cell infiltration that was common in both, COVID-19 patient lung had distinct features. The pulmonary vessels of COVID-19 patients had widespread thrombosis and microangiopathy. A significant increase in vascular angiogenesis via intussusceptive angiogenesis was observed. There was an increase in ACE2 expression in the endothelial cells and significant changes in endothelial morphology was observed in the lungs of COVID-19 patients. The endothelial cells were swollen and had disrupted intercellular junctions and the contact with basal membrane was lost. More interestingly, they demonstrated infection of endothelial cells with SARS-CoV-2 further supporting direct endothelial injury along with perivascular inflammation. Involvement of the endothelial system, endothelitis, endothelial dysfunction and thrombosis has been shown by others too in COVID-19 [56–58]. Besides viral infection, inflammatory host immune response and unrestrained complement activation plays a critical role in causing endothelitis and thrombotic events and intravascular coagulation [59].

3.2. Coagulation in COVID-19

Critically ill patients with an exacerbated inflammatory response have coagulation abnormalities [60]. Inflammation is known to initiate clotting, decrease anticoagulant mechanisms and inhibit fibrinolytic pathways. Severe infection and inflammation invariably lead to activation of the coagulation cascade and critical disseminated intravascular coagulation (DIC) which often results in multiorgan failure [61]. Thrombosis was observed in the lungs of 89% of COVID-19 patients who died [62]. Venous thromboembolism and both proximal and distal thrombosis are a feature of COVID-19 pneumonia [63,64]. These are caused by SARS-CoV-2-induced inflammation, hypoxia and diffuse intravascular coagulation [65]. A term pulmonary intravascular coagulation (PIC) was used to describe the lung restricted vascular thrombosis [66]. Due to the close proximity of pulmonary vasculature and pneumocytes, the numerous microthrombi in the vessels cause pulmonary infarction, hemorrhage and pulmonary hypertension. Vascular endothelial cells contribute to both inflammation and coagulation via growth factor release and by their adhesion molecules. Endothelial cells themselves release and respond to cytokines by increasing fibrin formation. Endothelial cells therefore play a critical role in maintaining patent and functional capillaries and endothelial dysfunction and vascular thrombosis may contribute significantly to pulmonary disease and COVID-19 severity [67]. It has also been suggested that SARS-CoV-2 can directly or indirectly activate toll-like receptors (TLRs), particularly TLR3 and TLR4, resulting in activation of extrinsic coagulation pathway [68]. The role of TLR3 [69] and TLR4 [70], in platelet function and the overall process of coagulation is also well known and thus their activation by SARS-CoV-2 further supports a connection between coagulation and COVID-19. A recently identified consensus pattern in SARS-CoV-2 spike protein (S protein) was similar to the sequence found in proteins involved in the coagulation process [71]. This further suggested involvement of the S protein in the molecular mechanisms leading to the COVID-related coagulopathy.

4. Inflammation and Cancer connection

The connection between inflammation and cancer is rather well

S. Ahmad et al. Seminars in Cancer Biology 83 (2022) 384–398

386
established with inflammation recognized as a critical component of tumor progression [4]. Inflammation predisposes to cancer and promotes all stages of tumorigenesis, namely, tumor initiation, progression and metastasis [72]. Tumor microenvironment, that plays an important role in tumor progression, is orchestrated by a number of inflammatory cells [4]. It is estimated that approximately 15–20% of cancers are a result of infections. The infections often result in inflammation with neoplastic transformation of surrounding cells leading to cancer, thus prompting the call to target inflammation for cancer prevention and therapy [73].

As discussed earlier, inflammation is intricately connected with several pulmonary diseases. Chronic pulmonary inflammation and fibrosis, following exposure to environmental toxins, can also result in lung cancer [74]. Lung cancer is the leading cause of cancer-related deaths worldwide [75,76] and by some estimates, smokers with COPD have up to six-fold increased risk of developing lung cancer, compared to smokers without COPD [77,78]. Given the inflammatory manifestations in smoking and COPD, these studies underscore the importance of inflammation in lung cancer. Further, a possible prognostic role of advanced lung cancer inflammation index (ALI) in cancer small cell lung cancer (NSCLC) patients has been suggested [79]. This index, calculated using the formula ‘Body Mass Index x Serum Albumin / Neutrophil Lymphocyte Ratio’, classifies NSCLC patients into those with low (ALI > 18) or high (ALI < 18) inflammation. The patients with high inflammation (and ALI < 18) have significantly lowered overall survival, compared to patients with low inflammation (and ALI > 18). On a similar note, another index, the systemic immune-inflammation index (SII) which is calculated using the formula ‘platelet counts x neutrophil counts / lymphocyte counts’ has been proposed as an independent prognostic factor for poor survival of advanced epidermal growth factor receptor (EGFR)-mutant NSCLC patients treated with first-generation tyrosine kinase inhibitors (TKIs) [80]. EGFR-targeted therapies, involving TKIs, are relevant to NSCLC [81,82] and clearly there seems to be a role of inflammation and immune response in sensitivity to TKIs.

Cigarette smoking is a major risk factor for lung cancer and the inflammatory as well as mutagenic effects of cigarette smoke promote a pro-cancer immune response [83]. The lungs of smokers are marked by activated macrophages, dendritic cells, lymphocytes and granulocytes, all resulting in an environment conducive to growth and proliferation of malignantly transformed cells [83]. However, smoking is not the only cause of lung cancer and lung cancer develops even in non-smokers potentially resulting from possible pulmonary infections, occupational dust exposure and IPF. Inflammation contributes towards lung cancer pathogenesis even in these patients [83]. A number of cellular and molecular factors mediate the inflammatory responses in lung cancer pathogenesis. The pro-inflammatory cyclooxygenase-2 (COX-2) [84] drives lung cancer progression and is a potential target for therapy [85]. Tumor associated macrophages (TAMs) are recruited within the lung cancer microenvironment wherein they induce production of several pro-inflammatory cytokines resulting in increased invasion, angiogenesis and metastasis of tumor cells. Even the tumor associated neutrophils (TANs) aid lung cancer tumorigenesis through increased expression of chemokine receptors such as CXCR3/4, CCR5/7 along with secretion of pro-inflammatory factors such as IL-6, IL-8 and MCP-1 [86]. IL-6 is produced at inflammation sites [87–89] and it promotes lung cancer metastasis [90]. High circulating levels of IL-6 associate with poor prognosis of lung cancer patients [91] thus making case for IL-6 blockage as an effective anticancer therapy [92]. Thus, similar to several pulmonary diseases discussed in the preceding section, inflammation is a major player in lung cancer tumorigenesis.

5. Lung cancer and COVID-19: the molecular link

A connection between cancer and COVID-19 has been suggested [93] (Fig. 2). Altered expressions of ACE2, TMPRSS2 and plasminogen activator inhibitor-1 (PAI-1), and elevated levels of various cytokines may particularly be relevant with regards to an association of cancer with COVID-19. The common symptoms associated with severe COVID-19 include flu-like symptoms and ARDS. Lung cancer patients are a high-risk group for SARS-CoV-2 infections and related complications [94,95]. In fact, it has been reported that lung cancer patients in each age group, subtype, and pathological stage are much more susceptible to SARS-CoV-2 infection [96]. Based on the emerging statistics that support high rate of hospitalization, onset of ARDS, and high mortality rate, lung cancer patients represent a vulnerable population for COVID-19 [97]. Further, SARS-CoV-2 has even been detected in the pleural fluid of a lung cancer patient [98] suggesting a connection between COVID-19 and lung cancer that is not yet completely understood. In the subsections to follow, we discuss a few important genes that are common to SARS-CoV-2 infection and lung cancer, and can help explain the possible association between the two diseases.

5.1. ACE2 and TMPRSS2 in COVID-19 and lung cancer

ACE2 is a cellular receptor for the viral entry of SARS-COV-2. Viral S protein utilizes ACE2 receptor to fuse into the host cell membrane or enter via endocytosis and this process is regulated by type II transmembrane serine proteases (TTSPs) such as the TMPRSS2 [99]. Lung is one of the major organs with elevated ACE2 levels and ACE2 expression is significantly elevated in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), compared to normal tissues [100,101]. ACE2 is a human interferon-stimulated gene in airway epithelial cells [102] and ACE2 and TMPRSS2 are co-expressed in lung epithelial cells [103]. Emerging data suggests that, compared to normal individuals, those with a history of smoking and lung cancer have increased risk for SARS-CoV-2 infection due to a higher expression of ACE2 and TMPRSS2 in their lung cells [104].

TMPRSS2 is actively involved in priming the S protein of SARS-CoV-2 and its proteolytic cleavage for infecting the host cells [105]. TMPRSS2 protein is encoded by the TMPRSS2 gene, which is widely conserved, and TMPRSS2 and ERG (ETS related oncogene) fusions are predominantly formed in tumors [106]. TMPRSS2 undergoes a developmental regulation and its expression is in a linear relationship with age in human beings [107]. Several reports have been made of the role of these proteins in causing infection and severity in case of COVID-19. The risk of this viral infection is enhanced in cancer patients as compared to non-cancer patients, owing to immunosuppression caused by malignancy or chemotherapy [108,109]. Since the primary site of infection of this virus is in the lungs, the worst outcomes are observed in the lungs [110]. Hence, lung cancer patients are believed to be at a

![Fig. 2. Key molecular factors connecting lung cancer and COVID-19. A number of key cell surface proteins and enzymes play parallel roles in lung cancer progression and SARS-CoV-2 infection. A majority of them seem to play a role in the entry of SARS-CoV-2 into host cells while also being reported to be elevated in metastatic lung cancers.](image-url)
higher risk of SARS-CoV-2 infection. Also, significant ACE2 expression level upregulation has been reported through immunohistochemistry in patients with lung cancer, more specifically in the lower airways [111]. These studies suggest an increased susceptibility of lung cancer patients to infection by SARS-CoV-2.

In a study that compared the gene expression of ACE2 and TMPRSS2 in different stages and subtypes of LUAD and LUSC with that of normal tissues [96], it was found that changes in expression levels of ACE2 and TMPRSS2 throughout different stages of lung cancer had no statistical significance except for the downregulation of TMPRSS2 in case of LUAD and that all stages of lung cancers are susceptible to the COVID-19 infection. It was speculated that this downregulation in LUAD and LUSC of TMPRSS2 could be due to its cancer suppressing properties. Comparison of ACE2 expression in different cancer tissues versus the corresponding normal tissues was also carried out in another independent study revealing a significant increase in ACE2 mRNA expression in LUAD and LUSC [112]. Another recent study [113] reported that ACE2 upregulation could actually have a protective effect in case of several different cancers including LUAD and LUSC, leading to better survival. This work suggested that several immune related pathways like T-cell receptor signaling and viral myocarditis were enhanced with high expression levels of ACE2. Further, ACE2 deficiency has been linked to a disruption of the renin-angiotensin system (RAS) that could result in an impaired immune response to virus infection more so in patients with prior underlying conditions [114]. Based on these reports, it is clear that our knowledge on the association between ACE2/TMPRSS2 expression and lung cancer is far from being conclusive, although there seems to be some trend supporting dysregulated ACE2 and TMPRSS2 expression in LUSC and LUAD patients, leading to increased susceptibility to SARS-CoV-2 infection for each stage of these lung cancer subtypes. Several studies have reported DNA methylation, histone modifications and glycosylation as underlying mechanisms responsible for the increased expression of ACE2 in lung cancers [100,115,116]. Further, vorinostat (SAHA), an HDAC inhibitor, upregulates ACE2 [117]. Thus, both methylation and acetylation seem to be involved in the epigenetic regulation of ACE2 levels.

5.2. PAI-1 in lung cancer and COVID-19

Hemostatic imbalance such as increased coagulation and fibrinolysis was reported in patients with freshly diagnosed carcinoma of the lungs [118]. Dense plasma fibrin networks indicative of increased coagulation activity was observed in a study of patients with advanced lung cancer [119]. Interestingly, the plasma clot phenotype was found to be driven by smoking as plasma cotinine levels correlated with fibrin content [119]. Venous thromboembolism (VTE) is a frequent complication of advanced-stage lung cancer and its treatment. Due to these reasons, thromboprophylaxis is emerging as a common clinical practice for lung cancer patients [120]. More recently occurrence of D-Dimer along with thrombotic risk factors guides clinicians to provide preventive anticoagulant therapy to patients that have undergone lung cancer surgery to reduce the incidence of VTE. Although plasma of lung cancer patients is enriched for coagulation factors, however, such a state of hypercoagulability is independent of lung cancer histology [121]. Plasma plasminogen activator inhibitor 1 (PAI-1) that participates in thrombotic, fibrinolytic, inflammatory and metabolic pathways is emerging as an important biomarker for non-small cell lung cancer [122].

Hypofibrinolytic state and high thrombin generation are also important in COVID-19 related thrombosis [123]. Plasma tissue plasminogen activator (tPA) and PAI-1 are highly elevated in hospitalized severe COVID-19 patients [124,125]. Therefore, PAI-1 is another factor that is common to lung cancer and COVID-19 (Fig. 2). It has been shown to promote lung cancer tumorigenesis [126]. Such pro-tumorigenic role of PAI-1 is rather paradoxical given that it is an endogenous inhibitor of oncogenic uPA/uPAR system [127]. However, PAI-1 is now regarded as a putative target for cancer therapy [128]. With regards to COVID-19, it has recently been proposed that SARS-CoV-2 gene products induce STAT-1 dysfunction which results in activation of STAT-3 as a compensatory mechanism [129]. While STAT-3 signaling is itself deregulated in lung cancer [130], in the SARS-CoV-2-infected cells, there is evidence for a positive feedback loop between STAT-3 and PAI-1 [129]. The activated PAI-1 leads to coagulopathy and secretion of pro-inflammatory chemokines and cytokines. Further, autopsies of COVID-19 patients exhibit diffuse alveolar damage and increased hyaluronan production, both of which induce PAI-1 levels [129]. This provides further evidence for enhanced PAI-1 levels in patients hospitalized with COVID-19 [125].

5.3. Other SARS-CoV-2-related genes in cancer

A number of other SARS-CoV-2 related genes, such as, basigin and paired basic amino acid cleaving enzyme (FURIN/PCKS3) have also been investigated in lung cancer [131] (Fig. 2). Basigin, also known as extracellular matrix metalloproteinase inducer (EMMPRIN) or cluster of differentiation 147 (CD147), is up-regulated in lung cancer and correlates with metastasis and poor prognosis overall survival [132-134]. It is a cell surface glycoprotein on tumor cells that stimulates the production of matrix metalloproteinases and vascular endothelial growth factor [135], all of which are known to be oncogenic and conducive to cancer metastasis. It is therefore not surprising that basigin family has been implicated in bone metastasis of lung cancers [136]. Basigin expressed on host cells is understood to interact with spike protein of SARS-CoV-2 facilitating the viral infection [137] leading to basigin being regarded as a potential target for COVID-19 treatment [138]. However, a recent report contradicting this theory has suggested no evidence of interaction between basigin and SARS-CoV-2 spike protein [139]. The knowledge in the field is rapidly emerging and more studies are needed to fully understand the role of basigin in SARS-CoV-2 infection.

The role of another SARS-CoV-2-related gene, furin, on the other hand, is relatively more established. Furin is essential for the proteolytic activation and entry of SARS-CoV-2 into the human airway cells [140]. The cleavage site for furin in the spike protein is critical for SARS-CoV-2 infection and pathogenesis [141]. This furin cleavage site has a unique insertion enabling cleavage of spike protein of just the SARS-CoV-2, and not the related SARS-CoV-1 or the Middle East Respiratory Syndrome coronavirus MERS-CoV [142]. This information has led to the identification of furin inhibition as a strategy to limit SARS-CoV-2 infection [143,144]. Furin has also been investigated in lung cancer and was reported to be expressed in all the tumors, with particularly elevated levels in NSCLC, the more common lung cancer subtype, relative to the small cell lung carcinomas [145]. Furin levels positively correlate with aggressive, metastatic cancers [146] and similar to inhibition of SARS-CoV-2 infection by furin inhibitors [147], furin inhibitors can inhibit the growth, proliferation and metastasis of lung cancer cells [148,149].

6. Epigenetic regulation of inflammation

Chromatin modifying epigenetic mechanisms such as histone methylation and acetylation are involved in pathogenic injury (such as those caused by environmental insults, oxidative stress and viruses and bacteria) and remodeling of pulmonary tissues that often lead to chronic diseases such as asthma and COPD. Moreover, as stated above, it is clear that inflammation is associated with a number of pulmonary diseases, cancer and COVID-19 and there has been considerable interest in understanding the mechanism(s) of inflammation, including the epigenetic basis of inflammation [10] (Fig. 3). This section focuses on methylation, acetylation and regulation through non-coding RNAs, the major investigated epigenetic pathways, in an attempt to summarize the current information on the topic.
Epigenetic regulation of inflammation. A number of epigenetic events can regulate inflammation. Modulators such as methylation and acetylation maintain a balance between heterochromatin and euchromatin with the relaxed euchromatin favoring transcription of genes. Histone acetyltransferases (HATs) and other proteins with similar activity such as bromodomain-containing protein 4 (BRD4) acylate histones while histone deacetylases (HDACs) remove acetyl groups from histones. Methylation of DNA and histones is carried out by methyltransferases while demethylases are responsible for demethylating action. Finally, regulation through non-coding RNAs (both long non-coding RNAs ‘lncRNAs’ and microRNAs ‘miRNAs’) also comprises epigenetic regulation of inflammation. The overall result of such epigenetic events is either induction or resolution of inflammation with induction of inflammation manifested by release of pro-inflammatory cytokines, chemokines and chemokine receptors along with mobilization of neutrophils/macrofages, elevated neutrophils-to-lymphocytes ratio (NLR) and coagulation. All these manifestations finally result in lung injury and pulmonary diseases characterized by chronic obstructive pulmonary disease (COPD) and/or acute respiratory distress syndrome (ARDS).

### 6.1. Role of methylation in inflammation

Epigenetic modulation of genes has been identified to regulate pro-inflammatory gene expression during the development of asthma, COPD and lung carcinogenesis [150]. Epigenetic processes are broadly carried out by DNA methylation, methylation/acetylation of histones, and non-coding RNAs. DNA methylation is the covalent binding of a methyl group to the 5'-carbon of cytosine (5mC) in cytosine-phosphate-guanine (CpG) dinucleotide sequence, mostly found in promoter/transcriptional/regulatory sites of genes [151]. DNA methyltransferases (DNMT) regulate DNA methylation and usually DNA methylation is associated with transcriptional repression while demethylation is associated with transcriptional expression of genes. Change in the status of DNA (e.g. in CpG-rich regions near transcriptional sites) and histone modifications has been identified to induce or suppress various oncogenes involved in lung cancerogenesis [152]. A study comparing DNA methylation and expression of inflammatory markers (IL-1β, IL-6 and IL-8) showed an inverse relationship between DNA methylation and transcriptional activation of these inflammatory genes in cancerous tissue as well as lung cancer cell lines [153]. Gene ontology analysis carried out on DNA extracted from peripheral blood of 1454 subjects identified altered methylation in 330 out of 349 CpG regions that influenced various genes, especially alpha-1-antitrypsin (AAT), involved in immune and inflammatory pathways contributing to pathogenesis of COPD [154]. Similarly, Bermingham et al., using 850K Illumina EPIC array, demonstrated that, out of twenty eight differentially methylated sites, two were associated with development of COPD [155]. Human lung epithelium the most environmentally exposed tissue [156]. DNA methylation profiles of peripheral blood lymphocytes from asthma patients have been very useful to identify the epigenetic change of immune status [158]. Since DNA CPG methylation changes are more reversible than mutation, many asthma treatment strategies including dietary manipulations have generated interest [159, 160]. Thus, methylation of genes affects expression of inflammation-related genes and methylation seems to be relevant in cancer as well as chronic pulmonary diseases such as asthma and COPD.

Other than the methylation of cytosine in CpG islands, DNA methylation has been reported in other sequences of DNA too which are gaining more attention in recent years. One such example is the methylation in cell-free DNA (cfDNA). It is well established that inflammation can drive necrosis and apoptosis of cells in COPD and lung cancer which results in release of cell-free DNA in blood [161–163]. Interestingly, methylation of cfDNA has been proposed as a diagnostic marker to differentiate between COPD, lung cancer and interstitial lung diseases [164]. Similarly, a comparative analysis between COPD patients and non-smokers revealed significant hyper-methylation in CpG regions of ANGPT1, PLD1, NFASC, ACTN4, RGS12, CAV1, PRKAG2, JARID2, HIPK2, and MECOM genes [165]. Caveolin-1 (Cav1) is known to regulate chronic inflammatory lung diseases and loss of CAV1 causes imbalance in the Th17/Treg cell in COPD patients [166]. A comparative study between ARDS patients and healthy individuals showed 30 DNA methylation sites were responsible for regulation of 10 genes that play critical role in inflammation, endothelial-epithelial barrier integrity and coagulation [167]. These studies are further corroborated by in vivo and translational studies. Mice intranasally exposed to inflammatory agent lipopolysaccharide (LPS) for two weeks reduced the global levels of cytokine hydroxymethylation (5hmC) in lung tissue [168]. Six weeks exposure to LPS increased cytokine methylation (5mC) in CDH13 (cell adhesion molecule), Ahr, Tet1 and Rassf1 (tumor suppressors) and DAPK1 (proto-oncogene) which together highlight involvement of
complex inflammatory stimulus involving methylation-based regulation of inflammation as well as tumor suppressors and oncoproteins in progression of lung cancer. Further, lung cancer cells, A549, treated with IL-1β, an inflammatory cytokine, resulted in methylation of promoter region of CDH1 and histones (H3K9Me2 and H3K9Me3 and H3K27Me) resulting in epithelial mesenchymal transition (EMT) of these cells [169], thus connecting epigenetics and inflammation with pro-tumorigenic event EMT. Similarly, chronic exposure to TNF-α and TNF-β exposure also led to increased DNA methylation in CDH-1 promoter regions [169]. Collectively, there is strong evidence suggesting that DNA methylation is a mechanism that plays critical role in inflammation and resulting pulmonary diseases and cancer.

6.2. Role of acetylation in inflammation

Acetylation is another well-established epigenetic modulator of gene expression. Addition of acetyl group to lysine (K) residues in histones as well as non-histone proteins directly influences the regulation of genes. Acetylation of proteins is carried out at two sites - N-terminal acetylation or ε-amino group of lysines [170,171]. Although the former is a co-translational modification and is more common, the latter is post-translational and less common but has diverse effects as it can modify protein function, and affect half-life, in addition to bringing about profound effects on the inflammatory process [171]. While addition of acetyl group is controlled by histone acetyltransferases (HAT), their catalysis is catalyzed by histone deacetylases (HDACs); thus, referred to as acetylation writers and erasers. The bromodomain and extra-terminal (BET) proteins categorized as readers of acetylation as they can recognize acetylated histones, are increasingly being recognized as mediators of inflammation. BETs have been shown to play crucial role in regulation of various genes involved in inflammation along with cell proliferation and apoptosis. The BET proteins namely BRD2, BRD3 and BRD4 mediate assembly of histone acetylation-dependent chromatin complexes that regulate expression of inflammatory genes [172]. BRD4 in this BET family not only identifies histone acetylation but also has HAT property, which is inducible by RelA activation [173]. BRD4 plays an important role in regulating inflammatory diseases through its direct interaction with NF-xB [172]. Moreover, BRD4 has been shown to be upregulated in airway inflammation which correlates with increased expression of IL-8 [174]. It has also been shown to play crucial role in IL-1β-induced inflammation in human airway epithelial cells and TLR3 mediated airway remodeling and virus induced lung infection [175,175,176]. Interestingly, treatment of lung epithelial cells with IL-1β or TNF-α results in acetylation of H4K which increases expression of granulocyte colony stimulating factor (GM-CSF) signifying role of HATs in inducing an inflammatory phenotype [177]. Similarly, pharmacologic inhibition of HDACs by Trichostatin A (TSA) leads to activation of various inflammatory cytokines while drugs like theophylline which restore histone deacetylase activity have opposing effects [178,179]. In inflammatory lung disease, such as asthma, increased expression of HATs and decreased expression of HDACs in the lung tissues has been observed [180]. Similarly, analyses carried out on lung inflammatory cells of asthmatics showed decreased HDAC activity [181]. In COPD patients, disease severity correlated with HDAC activity, which was shown to be reduced by >95 % in severely sick patients [182]. While HATs are increased in asthma, they are not much affected in COPD [182,183]. Rats exposed to cigarette smoke showed reduced HDACs activity which resulted in increased NF-xB activation [184]. Similarly, smoking in otherwise healthy individuals did not alter HAT expression but greatly reduced activity of HDACs in alveolar macrophages [185]. The importance of acetylation in the pathogenesis of inflammatory lung diseases is underscored by the fact that corticosteroids, which are known to reverse histone acetylations, are frequently used for treatment of such conditions. Lung inflammatory diseases are multifactorial and involve activation of various transcriptional factors like NF-xB, AP-1, signal transducer and activator of transcription (STAT), and nuclear factor of activated T-cells (NF-AT). Activation of these factors leads to histone acetylation and subsequently inflammation. However, it is through these transcriptional factors that corticosteroids prevent acetylation of histones and consequently suppress inflammation by switching off induced inflammatory genes [183]. Acetylation/deacetylation of glucocorticoid receptors is linked to secretory leukocyte protease inhibitor expression which is found in upper airways and regulates neutrophil elastase activity [186]. In COVID-19, hypomethylation of ACE2, frequently observed in lupus patients, has been suggested to increase SARS-CoV-2 entry [187]. Based on the collective evidence presented here, it is clear that the dynamic processes of acetylation and deacetylation regulate the expression of genes that connect inflammation with various pulmonary diseases.

6.3. Role of non-coding RNAs in inflammation

In recent years there has been considerable interest in the regulation of signaling pathways by non-coding RNAs in various human diseases [188]. Targeting non-coding RNAs, such as long non-coding RNAs (lncRNAs) [189-191] and miRNAs [192,193] can modulate inflammation and the associated immune responses [191]. Non-coding RNAs are a large class of RNA molecules with new members being identified regularly. They are extremely diverse in their functionality and individual non-coding RNAs modulate multiple signaling pathways. For example, lncRNAs, the non-coding RNAs longer than 200 nucleotides, can enhance or suppress transcription of inflammatory responses [194]. lncRNA H1X03209 [195], ROCKI [196], Rpphi [197], HOTAIR [198] are some of the lncRNAs that promote inflammation while IncFAO [190], Mirt2 [199], PMS2L2 [200], AF131217.1 [201] are some of the lncRNAs that inhibit inflammation. These IncRNAs bring about their physiological effects by interacting with multiple molecular targets. This includes sponging of miRNAs and transcriptional as well as post-transcriptional regulation of target genes.

MicroRNAs, the non-coding RNAs that are much shorter and about 20–24 nucleotides long, similarly regulate inflammation through the down-regulation of their target genes. The available literature on the regulation of inflammation and the related signaling mechanisms by miRNAs is rather vast and beyond the scope of discussion here and reviewed in detail elsewhere [202-208]. However, similar to the regulation by lncRNAs, miRNAs have also been reported to regulate inflammation. miR-20a [209], miR-15b [210], miR-106a [211], miR-155 [212], miR-421 [213] and miR-1307 [214] are some of the miRNAs that promote inflammation while miR-10a [215], miR-24 [216], miR-124 [217], miR-146a [218], miR-181 [219] and miR-223 [220] are some of the miRNAs that inhibit inflammation. Based on such information, it is clear that non-coding RNAs have the potential to effectively regulate inflammation and related processes. There is enormous data on such activity by miRNAs and data on IncRNAs is emerging. Targeting these non-coding RNA molecules can provide an opportunity to tweak the overall process of inflammation and its impact on affected diseases.

6.4. Epigenetic regulation of inflammatory cytokines

6.4.1. Interleukin-6

Pro-inflammatory cytokines are produced predominantly by activated immune cells which trigger inflammatory reactions. Based on the earlier reports and our own findings [89,221], IL-6 is clearly an important pro-inflammatory cytokine in pulmonary and non-pulmonary diseases, which can be regulated epigenetically. IL-6 in turn, can epigenetically regulate other molecular factors. Its inhibition of methyltransferases DNMT1 [222] and DNMT3B [223] can possibly impact expression and activity of multiple genes. Not only a direct but even some indirect epigenetic regulation of IL-6 has been suggested. For example, in cancer, methylation and resulting repression of suppressor
of cytokine signaling-1 (SOCS-1) can activate IL-6 as SOCS-1 is involved in the negative regulation of IL-6 [224].

IL-6, which is epigenetically regulated by miRNAs, can itself regulate miRNAs as well. For instance, the miRNAs, let-7 [225] and miR-149 [226] have been shown to target and inhibit IL-6. In turn, IL-6 can down-regulate miR-370 when ectoptically overexpressed [227]. IL-6-mediated regulation of miR-370 possibly involves methylation, as the effect was decreased by the methylation inhibitor 5-aza-2′-deoxycytidine [227]. Similarly, IL-6 methylates and inhibits miR-142 [228]. In addition to regulation of miRNAs, IL-6 has been reported to affect methylation of some genes as well. IL-6 can elicit the loss of methylation at the promoters of cancer stem cell markers CD133 and CD44 [229]. Interestingly, such epigenetic action by IL-6 is possible only after the loss of tumor suppressor p53 that results in demethylation at IL-6 promoter and its consequent expression [229].

In dendritic cells that play important role in inflammation-induced ARDS [230], IL-6 is activated by the transcription factor Kruppel-like factor 4 (KLF4). However, instead of methylation which seems to be the most common mechanism of IL-6 activation, the effect of KLF4 involves acetylation [231]. The role of acetylation in IL-6 activation is further supported by the observation that the activation is inhibited by inhibition of acetyltransferase activity [232]. Further, there is evidence that IL-6 is demethylated and thus epigenetically activated in response to influenza virus infection [233]. Also, herpesvirus encoded viral IL-6 can induce STAT3 activity through phosphorylation as well as acetylation [234] thus supporting a robust role of IL-6-mediated epigenetic regulation in viral infections. In particular, IL-6 needs to be better scrutinized in the context of COVID-19 pandemic because a number of recent reports correlate elevated levels of IL-6 with the severity and mortality of COVID-19 [235-238].

6.4.2. Other inflammatory cytokines

A plethora of studies have established the involvement of proinflammatory cytokines in lung disease pathogenesis. The differentiation of Th1/Th2 cells mediate inflammatory/immune responses in pulmonary diseases through action of cytokines like IL-4, IL-13, IL-5 and IFN-γ. IFN-γ is suppressed by the methyltransferase DNMT3a, which methylates CpG-53 [239]. Similarly, CpG demethylation at DNase I hypersensitive sites (DHS) in the promoter regions of IL-4 and IL-13 regulate Th2 differentiation [240]. In parasitized induced pulmonary fibrosis model, imbalance in HATs and HDAC has been shown to regulate IL-6 expression [232]. DNA methylation in promoter region has been shown to regulate STAT-6 and respective cytokines [241]. The interaction between CXCR4 and CXCL12 regulates cancer progression in various organs including lungs and it has been shown that demethylation of CXCR4 and hypermethylation of CXCL12 promoter regions is responsible for their activation [153]. A similar report published on granulomatous lung diseases shows involvement of methylation in the regulation of cytokine-cytokine receptor interaction, chemokine signaling and JAK-STAT pathway and cellular immunity [242]. Methylation of CpG islands in promoter regions of IL-1β, IL-6, and IL-8 genes have been shown to regulate the pathogenesis of lung cancer [243].

Disregulation of histone acetylation and deacetylation also influences transcription of inflammatory cytokines, subsequently affecting the expression of inflammatory genes [244]. CXCL-10, an anti-inflammatory cytokine is possibly reduced in IPF and other inflammatory lung diseases due to acetylation on H3 and H4 histones [245]. In COPD, HDAC reduction is responsible for over expression of GM-CSF, IL-8 and TNF [185]. Other cytokines like interleukin-23 (IL-23) or receptors of some cytokines e.g. that of IL-12 are regulated by histone acetylation as well as methylation. IL-12 receptors are regulated in NSCLC cells and COPD by both histone acetylation and DNA methylation [246]. In experimental asthma DNA methylation has been shown to be involved in effector T-cell polarization causing differential secretion of TH1 and TH2 cytokines [247]. Here increase in DNA methylation at the interferon gamma promoter correlated with interferon gamma cytokine production [247,248]. In SARS-CoV-2 infected patients, cytokine storm has been reported in which there are massive increases in inflammatory cytokines, such as, interleukins, TNF, colony stimulating factors (CSFs), and growth factors (GFs). Emerging evidence suggests the involvement of epigenetic modifications in these increases [249,250]. Variable response of individuals infected with SARS-CoV-2 could possibly be influenced by epigenetic regulators of cytokines, as has been reported in lupus patients [187]. Thus, there is convincing evidence to support epigenetic regulation of inflammatory cytokines that are involved in onset/progression of lung cancer, pulmonary diseases and COVID-19.

7. MicroRNAs as epigenetic regulators connecting inflammation, lung cancer and COVID-19

As discussed above, there are numerous reports supporting a role of miRNAs in the regulation of inflammation. Given the connections between inflammation, lung cancer and COVID-19, we surveyed the literature to evaluate possible epigenetic links. The roles of miRNAs in inflammation [202-208] and lung cancer [251-254] are well established and recent literature suggests role of miRNAs in COVID-19 infections as well. For example, it has been suggested that immune responses to various viral respiratory infections, including COVID-19, are characterized by ectopic expression of miRNAs [255]. Also, some recent studies have listed the potential miRNAs that can target COVID-19-related host receptors, ACE2 or TMPRSS2, in SARS-CoV-2-infectable liver cancer cells HuH7 and lung cancer cells Calu3 [256], kidneys [257], cardiomyocytes [258] as well as in the hypothalamus [259]. A possible role of deregulated miRNAs has also been suggested in the relatively higher COVID-19 related mortality in elderly patients [260]. This section discusses some miRNAs that have been predicted/reported to be relevant to COVID-19, lung cancer and inflammation (Table 1).

A few studies have looked at the miRNAs that can potentially target SARS-CoV-2 genome. One such study reported miR-1307 as the miRNA with highest affinity for the SARS-CoV-2 genome [261]. This oncogenic miRNA associates with poor survival of lung cancer patients [262] and has been reported to promote inflammatory response [214]. In an in silico study, miR-29 family of miRNAs were found to have the most binding sites (11 sites) on SARS-CoV-2 genome [263]. Members of this family have been reported to exert tumor suppressive effects in lung cancer with role in sensitivity to cisplatin [264,265], and also found to antagonize inflammatory mechanisms in multiple diseases [266,267]. A computational approach, that evaluated interactions between miRNAs and seven human coronavirus RNAs, predicted miR-21 to be the most likely miRNA that can bind to human coronavirus RNAs resulting in potential significantly upregulated expression in human lungs after COVID-19 infection [268]. miR-21 is an oncogenic miRNA [269] whose important role in the regulation of inflammatory responses has previously been described [270].

Mir-200 family has been well characterized in cancer with numerous reports on its tumor suppressive action in multiple human cancers [271,272], including in lung cancer [81,273]. Members of this family can regulate ACE2, with miR-200c possibly the strongest candidate miRNA that can target ACE2 in respiratory cells [274]. Additionally, members of miR-200 family have been reported to regulate inflammation. They have multifaceted effects on inflammation ranging from pro-inflammatory [275,276] to anti-inflammatory [277], which might be tissue/cell-specific and may also depend on the stimulus. Interestingly, miR-200c was found to be down-regulated in lungs of COPD model mice and it was proposed as a potential therapy to treat COPD because of its ability to attenuate inflammatory responses [278]. miR-200 family is however not the only one that can regulate ACE2. Regulation of ACE2 has also been shown with miR-421 [279]. This miRNA is upregulated in lung cancer and associates with poor prognosis of lung cancer patients
It was reported that miR-15b and miR-195 are predicted to bind to the RNA of host viral entry proteins such as ACE2. This study was conducted using lung endothelial cells and such validation has been found to aggravate inflammation in lung tissues [213]. With regards to inflammation, ectopic up-regulation of miR-421 has been shown to result in diminished levels of pro-inflammatory cytokines [282] and reduced proliferation and metastasis in lung cancer [283]. Kim et al. tested the in vivo significance of miRNAs identified by bioinformatic tools and predicted to bind to the RNA of host viral entry proteins such as ACE2, TMPRSS2, and ADAM17. It was reported that miR-15b and miR-195 are significantly differentially expressed in Hamster lung tissues after infection with SARS-CoV-2 [284]. There is evidence to suggest a pro-inflammatory function of miR-15b [210] but, conversely, an anti-inflammatory function of miR-195 [285]. Consequently, while miR-15b promotes growth and invasion of lung cancer [286], miR-195 represses lung cancer and associates with improved recurrence-free and overall survival of lung cancer patients [287].

In a study that assessed role of miRNAs in COVID-19-induced acute inflammatory response, an essential role of miR-1207 in the process was identified [288]. It was revealed that miR-1207, which suppresses lung cancer progression and metastasis through the targeting of colony stimulating factor-1 (CSF1) [289], is itself targeted by SARS-CoV-2 RNA. The competitive binding of SARS-CoV-2 RNA to miR-1207 de-represses CSF1 which then induces the characteristic inflammatory response associated with COVID-19 infection [288]. This fits well with the narrative that pathogenic human coronaviruses, including SARS-CoV-2, can regulate host miRNA levels by acting as miRNA sponges [290].

Given the growing evidence for the role of miRNAs in COVID-19 infection, their putative use in COVID-19 therapy, with possibility of employing extracellular vesicles-based delivery approach, has been advocated [291,292]. The progress in the therapeutic targeting of miRNAs for the benefit of lung cancer patients in clinical settings has been extremely slow. Hopefully, the scale of current COVID-19 global pandemic can incentivize researchers to accelerate studies that can help realize clinical potential of miRNAs.

8. Conclusions and perspectives

The relationship of inflammation with several pulmonary ailments and lung cancer is irrefutable as is the connection between pulmonary diseases and lung cancer, both in terms of pre-disposition as well as disease etiology. Over the past several months, emergence of COVID-19 has led to a lot of resources been diverted to better understand this disease. Even though the mortality rate associated with COVID-19 is low and not even comparable to many other diseases, its high infection rate has resulted in worldwide cases exceeding 68 million, resulting in more than 1.5 million deaths as of this writing during the first week of December, 2020. All the available data points to significant overlap between COVID-19 and pulmonary manifestations, and COVID-19 patients often succumb to the disease as a result of pulmonary complications. There is also a definite connection of COVID-19 with lung cancer, as lung cancer patients not only represent a more vulnerable group for SARS-CoV-2 infections but also correlate with higher mortality rates. As discussed in this article, a number of genes crucial for SARS-CoV-2 infection have also been implicated in tumorigenesis, thus explaining the COVID-19-lung cancer connection. As a mechanism, we have provided evidence connecting inflammation with pulmonary diseases, lung cancer and COVID-19, and focused on the epigenetic regulation of inflammation, including dysregulated miRNA, as this might represent novel opportunity to therapeutically target inflammation.

One of the limitations with the studies that have emerged lately during the COVID-19 pandemic is that several of these reports have been conducted on a relatively small-scale, and, additionally, a large amount of such emerging data has also been made available before the traditional peer-review. A more robust review, validation and confirmation by independent groups is needed before reaching any definitive conclusions. Regardless, it is quite apparent that inflammation, particularly the various epigenetic targets as well as modifiers of inflammation need to be further evaluated in relation to their ability to regulate pulmonary diseases, thus impacting both lung cancer and COVID-19. As an example, a number of mechanistic studies have identified the critical role of cytokines in inflammation-mediated disease etiology, with definite evidence connecting epigenetic regulation of cytokines with their expression and function. This supports the notion that a combined cytokine panel can improve the accuracy of predictive value for adverse outcome beyond standard clinical data alone [293]. This also provides opportunity for the identification of specific cytokines to stratify patients towards trials of specific immunomodulatory treatments to improve outcomes in COVID-19. Clearly, such personalized therapy involving cytokines can be beneficial for lung cancer patients as well, given the overwhelming data on cytokines in lung cancer progression. With the focus on inflammation and the resulting pulmonary manifestation, it is possible to fine tune our current understanding of lung cancer and COVID-19 with possible implications on how these diseases can be managed and treated.

Table 1
miRNAs connecting COVID-19, lung cancer and inflammation.

| miRNA   | SARS-CoV-2 target                              | Role in Lung Cancer                      | Role in Inflammation                       |
|---------|-----------------------------------------------|------------------------------------------|--------------------------------------------|
| miR-15b | Differentially expressed in Hamster lungs after SARS-CoV-2 infection [284] | Promotes lung cancer growth and invasion [286] | Expression positively correlates with inflammation [210] |
| miR-21  | Predicted to bind to human coronavirus RNA [268] | Oncogenic miRNA in lung cancer [269] | Regulator of inflammatory response [270] |
| miR-29 family | Has 11 binding sites on SARS-CoV-2 genome [263] | Tumor suppressor with role in therapy resistance [265,266] | Anti-inflammatory in cancer and other diseases [266,267] |
| miR-98 targets TMPRSS2 in lung endothelial cells [281] | Inhibits lung cancer proliferation and metastasis [283] | Expression negatively correlates with inflammatory cytokines [282] |
| miR-195 | Differentially expressed in Hamster lungs after SARS-CoV-2 infection [284] | Tumor suppressor that associates with improved survival [287] | Promotes resolution of inflammation [285] |
| miR-200 family | miR-200c is predicted to regulate ACE2 in respiratory cells [274] | Tumor suppressor and negative regulators of EMT [81,273] | Members of this family have been reported to be pro-inflammatory [275,276] as well as anti-inflammatory [277,278], |
| miR-421 | Regulates ACE2 [279] | Overexpressed in lung cancer and associates with poor prognosis [280] | Aggravates inflammatory response in lung tissues [213] |
| miR-1207 targeted directly by SARS-CoV-2 RNA [288] | Tumor suppressor with inhibitory effect on metastasis [289] | De-repression of its target CSF1 results in acute inflammatory response in COVID-19 [288] |
| miR-1307 predicted to have highest affinity for SARS-CoV-2 genome among 1872 miRNAs [261] | Promotes lung cancer growth and proliferation [262] | Promotes inflammatory responses [214] |

Numbers in parenthesis are corresponding citations. CSF1: Colony Stimulating Factor 1, EMT: Epithelial-to-Mesenchymal Transition.
Funding

This work is funded by grants from the CounterACT Program, National Institutes of Health Office of the Director (NIH OD), the National Institute of Environmental Health Sciences (NIEHS) Grants, U01ES025069 (Aftab Ahmad), U01ES028182 (SA) and the National Heart Lung and Blood Institute (NHLBI) grant numbers RO1HL14933 (Aftab Ahmad).

Declaration of Competing Interest

None of the authors have any potential conflict of interest to report.

References

[1] K.L. Rock, H. Kono, The inflammatory response to cell death, Annu. Rev. Pathol. 3 (2008) 99–126.
[2] R. Pahlwa, A. Goyal, P. Bansal, I. Jialal, Chronic Inflammation, StatPearls, Treasure Island (FL), 2020.
[3] V. Čukic, V. Loeve, D. Dragic, A. Ustumujic, Asthma and chronic obstructive pulmonary disease (COPD) - differences and similarities, Mater. Sociomed. 24 (2) (2012) 100–105.
[4] M.L. Cousoons, Z. Werb, Inflammation and cancer, Nature 420 (6917) (2002) 860–867.
[5] F. Balkwill, A. Mantovani, Inflammation and cancer: back to Vichow? Lancet 357 (9251) (2001) 539–545.
[6] M. Gomes, A.L. Teixeira, A. Coelho, A. Araujo, R. Medeiros, The role of inflammation in lung cancer, Adv. Exp. Med. Biol. 816 (2014) 1–23.
[7] E. Marklova, Inflammation and genes, Acta Medica Irlandica (Irlande) 50 (1) (2007) 17–21.
[8] Y. Zhao, C.V. Forst, C.E. Sayyah, I.M. Wang, X. Yang, B. Zhang, Molecular and genetic inflammation networks in major human diseases, Mol. Biosyst. 12 (8) (2016) 2318–2341.
[9] E.A. Newcombe, J. Camats-Perna, M.L. Silva, N. Valmas, T.J. Huat, R. Medeiros, Epigenetic mechanisms in inflammation, J. Dent. Res. 90 (1) (2011) 9–17.
[10] D. Bayarsaihan, I. Donkin, S. Versteyhe, R. Barres, D. Simmer, The emerging role of epigenetics in inflammation and immunometabolism, Trends Endocrinol. Metab. 27 (11) (2016) 782–795.
[11] A. Ahmad, Y. Li, B. Bao, D. Kong, F.H. Sarkar, Epigenetic regulation of mRNAs in cancer stem cells nexus by nutraceuticals, Nutr. Mol. Food Res. 58 (3) (2014) 79–86.
[12] E. Siyanbola, Epigenetics of chronic inflammatory diseases, J. Inflamm. Res. 12 (2019) 1–14.
[13] E.D. Bateman, S.S. Hurd, P.J. Barnes, J. Bouquot, J.M. Drazen, J.M. FitzGerald, P. Gibson, K. Ohta, P. O’Byrne, S.E. Pedersen, E. Pizzichini, S.D. Sullivan, S. Wenzel, H.J. Zarr, Global strategy for asthma management and prevention: GINA executive summary., Eur. Respir. J. 31 (2008) 148–178, Eur Respir J 51 (2018).
[14] L.B. Ware, M.A. Matthay, The acute respiratory distress syndrome, N. Engl. J. Med. 342 (18) (2000) 1334–1349.
[15] P.J. Barnes, Chronic obstructive pulmonary disease, N. Engl. J. Med. 343 (4) (2000) 269–280.
[16] P.J. Barnes, Immunology of asthma and chronic obstructive pulmonary disease, Nat. Rev. Immunol. 8 (3) (2008) 183–192.
[17] B. Moldaveanu, P. Omisti, P. Jani, J. Walker, X. Sarmiento, J. Guardiola, M. Saad, J. Yu, Inflammatory mechanisms in the lung, J. Inflamm. Res. 2 (2009) 1–11.
[18] C.T. Robb, K.H. Regan, D.A. Dorward, A.G. Rossi, Key mechanisms governing resolution of lung inflammation, Semin. Immunopathol. 38 (4) (2016) 425–448.
[19] P. Aghasafari, U. George, R. Pidaparti, ACE2 expression, J. Immunol. 172 (4) (2004) 2668–2674.
[20] S. Nakano, L. Sun, M.I. Fulcher, A. Livraghi-Butrico, N.I. Nicely, M. Cameron, C. Cameron, D. J. Kelvin, A. de Silva, D.M. Margolis, A. Markmann, L. Bartelt, R. Zumwalt, F. J. Martinez, S.P. Salvador, A. Borczak, P.R. Tata, V. Sontake, A. Kimple, L. Jaspers, W.K. O’Neal, S.H. Randell, R.C. Boucher, S. Baric, SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract, Cell 182 (2) (2020) 442–416 e4.
[21] R. Wolff, V.M. Corman, W. Guggekemohr, M. Seilmair, S. Zange, M.A. Muller, D. Niemeyer, T.C. Jones, P. Vollmar, C. Rothe, M. Hoelscher, T. Bleicker, S. Brunkin, J. Schneider, R. Ehmann, K. Zwingrajner, D. Crosten, C. Wendtner, Virological assessment of hospitalized patients with COVID-19, Nature 581 (7809) (2020) 465–469.
[22] M. Nawjia, W. Timmins, Can ACE2 expression explain SARS-CoV-2 infection of the respiratory epithelia in COVID-19? Mol. Syst. Biol. 16 (7) (2020) e9841.
[23] H. Zhang, M.R. Rastori, P.L. Jefferson, J.G. Mezey, S.L. O’Beirne, Y. Srowulovic-Barel, R.G. Crystal, Expression of the SARS-CoV-2 ACE2 receptor in the human airway epithelium, Am. J. Resp. Crit. Med. 202 (2) (2020) 219–229.
[24] P.E. Lazzerini, M. Boutjdir, P.L. Capecchi, COVID-19, arrhythmic risk, and myocardial remodelling, Circulation 142 (1) (2020) 7–9.
[25] K. Lash, K.H. Reilly, W.P. Pulver, D. Thomas, K.A. Feder, K.K. Hsu, N. Plipat, G. Richardson, H. Reid, S. Schmitz, T. Pierce, H. Srpacak, D. Datta, S. B. Morris, K. Clarke, E. Belsky, California MIS-C response Team COVID-19: Associated multisystem inflammatory syndrome in children - United States, march-july 2020, MMWR Morb. Mortal. Wkly. Rep. 69 (32) (2020) 1074–1080.
[26] S. Qian, J. An, F. Qi, L. Ye, Q. Chen, L. Xie, G. Li, Tocilizumab exerts anti-inflammatory activity by expression of IL-6 receptor in alveolar epithelial cells, Am. J. Physiol. Lung Cell Mol. Physiol. 280 (6) (2001) L1258–65.
[27] N. Elia, M. Tapponeer, M.A. Matthay, J. Hamacher, J.C. Pache, M.A. Brundler, M. Totsch, P. De Baetselier, L. Fransen, N. Kuffa, D.R. Morel, R. Lucas, Functional identification of the alveolar edema reabsorption activity of murine tumor necrosis factor-alpha, Am. J. Resp. Crit. Med. 168 (9) (2003) 1043–1050.
[28] E. A. Newcombe, J. Camats-Perna, M.L. Silva, N. Valmas, T.J. Huat, R. Medeiros, Silencing of INOS reduces lung inflammation, J. Immunol. 172 (4) (2004) 2668–2674.
[29] S. Gando, T. Kameue, N. Matsuda, A. Sawamura, M. Hayakawa, H. Kato, Systemic inflammation and disseminated intravascular coagulation in early stage of ALI and ARDS: role of neutrophil and endothelial activation, Inflammation 28 (4) (2005) 237–244.
[30] M.A. Olman, K.E. White, L.B. Ware, W.L. Simmons, E.N. Benveniste, S. Zhu, J. Pugin, M.A. Matthay, Pulmonary edema fluid from patients with early lung injury stimulates pro-resolving lipid PUFAs through IL-1 beta-induced IL-6 expression, J. Immunol. 172 (4) (2004) 2668–2677.
[31] N. Fukuda, C. Jayar, A. Lazrak, Y. Wang, R. Lucas, S. Matalon, M.A. Matthay, Mechanisms of TNF-alpha stimulation of amiloride-sensitive sodium transport across alveolar epithelium, Am. J. Physiol. Lung Cell Mol. Physiol. 280 (6) (2001) L1258–65.
L. Montrose, T.J. Ward, E.O. Semmens, Y.H. Cho, B. Brown, C.W. Noonan, Dietary
Supplements and nutrients, J. Allergy Clin. Immunol. 133 (5) (2014) 1246-1254.

A. Szpechcinski, J. Chorostowska-Wynimko, R. Struniawski, W. Kupis,
Pulmonary fibrosis and COPD, EBioMedicine 2 (8) (2015) 929-936.

A.H. Sawalha, M. Zhao, P. Gout, Q. Lu, Epigenetic dysregulation of ACE2 and
interleukin-1ra regulates renal function, J. Am. Soc. Nephrol. 32 (4) (2011) 563-570.

A. Ahmad, Non-coding RNAs: A tale of junk turning into treasure, Noncoding
RNA Res. 1 (1) (2016) 1-2.

C.L. Chew, S.A. Conos, B. Unal, V. Tergaonkar, Noncoding RNAs: Master
Regulators of Inflammatory Signaling, Trends Mol. Med. 24 (1) (2018) 66-84.

A. Nail, Y. Fujii, K. Ruki, Y. Oishi, M.S. Morioka, T. Ishagawa, J. Matsuda,
Lung Cell Mol. Physiol. 313 (6) (2017) L1058.

B. Marcu, E. Kolettas, Roles of NF-kappaB signaling in the regulation of miRNAs
in inflammation-related carcinogenesis, Curr. Pharm. Des. 21 (21) (2015)
21.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.

S. Ahmad et al. 2022: S. Ahmad et al. 2022: 2454.
G.Y. Chiou, C.S. Chien, M.L. Wang, M.T. Chen, Y.P. Yang, Y.L. Yu, Y. Chien, Y.L. Hu, Y. Yu, H. Huang, H. Fan, L. Hu, C. Yin, K. Li, D.J. Fulton, F. Chen, Q. Notz, M. Schmalzing, F. Wedekink, T. Schlesinger, M. Gernert, J. Herrmann, W. Li, Q. Wang, X. Qi, Y. Guo, H. Lu, Y. Chen, Z. Lu, Q. Yan, X. Zhu, J.U. Jung, F. Meng, H. Wehbe-Janek, R. Henson, H. Smith, T. Patel, Epigenetic regulation of P. Li, J.X. Shan, X.H. Chen, D. Zhang, L.P. Su, X.Y. Huang, B.Q. Yu, Q.M. Zhi, C. Y.T. Xiao, J. Wang, W. Lu, Y. Cao, W. Cai, Downregulated expression J.B. Fordham, A.R. Naqvi, S. Nares, miR-24 regulates macrophage polarization R.M. O
S. Ahmad et al. J. Wischhusen, P. Meybohm, C. Lotz, Pro- and anti-inflammatory responses in R.M. O

severe COVID-19-induced acute respiratory distress syndrome—an observational study, PLoS. Immunol. 11 (2020) 581336.

J. Zhou, Y. Wang, W. Wu, X. Ou, F. Ming, G. Liang, V. Qian, Q. Cai, S. Dong, S. Hu, W. Wang, S. Wei, Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study, J. Transl. Med. 18 (1) (2020) 406.

J.S. Kwon, J.Y. Kim, M.C. Kim, S.Y. Park, B.N. Kim, S. Bae, H.H. Cha, J. Jung, M. Ju, M.J. Lee, S.H. Shin, S.H. Kim, Factors of severity factor-alpha, as potential biomarkers of severity and mortality for COVID-19: systematic review with meta-analysis, J. Clin. Immunol. (2020).

J. Jones, C. Lin, Inhibition of HIF-1 gamma expression during type-specific methylation during 7 helper cell development, EMBO J. 25 (11) (2006) 2443-2452.

D.U. Lee, S. Agarwal, A. Rao, Th2 lineage commitment and efficient IL-4 production involves extended demethylation of the IL-4 gene, Immunity 16 (5) (2002) 469-660.

Y. Liu, H. Li, T. Xiao, Q. Lu, Epigenetics in immune-mediated pulmonary diseases, Clin. Rev. Allergy Immunol. 45 (3) (2013) 314-336.

L.V. Yang, J. Konigeborg, K. MacPhail, L. Li, E.J. David, P.M. Mor, N. Hanzeb, M. Gillespie, L.J. Silveira, T.E. Fingerlin, L.A. Maier, DNA methylation changes in lung immune cells are associated with granulomatous lung disease, Am. J. Respir. Cell Mol. Biol. 60 (1) (2019) 96-105.

A.M. Baird, J. Leonard, K.M. Naicker, L.K. Kilimann, K.J. O’Byrne, S.G. Gray, IL-23 is pro-inflammatory, epigenetically regulated and modulated by chemotheraphy in non-small cell lung cancer, Lung Cancer 79 (1) (2020) 3-13.

L.X. He, Z.H. Tang, Q.S. Huang, W.H. Li, DNA methylation: A Potential Biomarker for Lung Cancer Progression, Front. Cell Dev. Biol. 8 (2020) 587.

R.V. Bowman, C.M. Wright, M.R. Davidson, S.M. Francis, I.A. Yang, K.M. Fong, Epigenetic targets for the treatment of respiratory disease, Exp. Opin. Ther. Targets 13 (6) (2009) 625-640.

M. Suzuki, H. Suda, S. Ota, T. Makino, L. Tian, H. Shimogame, H. Suzuki, M. Alaa, H. Tamura, T. Fujisawa, K. Nagato, S. Motohashi, Y. Moriya, H. Hoshino, S. Yoshida, K. Shibuya, K. Hiroshima, Y. Nakatani, Y. Yoshih, Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through an analysis and alterations of EGFR signaling, Am. Surg. Oncol. 17 (3) (2010) 878-888.

J. Brand, D.A. Kesper, R. Teich, E. Kilic-Niebergall, P. Torkel, E. Henn, M. Lohoff, H. Garm, P.I. Pfeiferle, H. Henz, DNA methylation of TH1/TH2 cytokine genes affects sensitization and progression of experimental asthma, J. Allergy Clin. Immunol. 129 (6) (2012), 1602-6.

M. Kabesch, J. Tost, Recent findings in the genetics and epigenetics of asthma and allergy, Semin. Immunopathol. 42 (1) (2020) 43-66.

K. McCoy, A. Peterson, T. Yian, S. Yang, Immunogenetic association underlying severe COVID-19, Vaccines (Basel) 8 (4) (2020).

A. Salkowska, I. Karwacjaciak, K. Karas, J. Dastych, M. Rajawali, SARS-CoV-2 proteins induce IFNG in Th1 lymphocytes generated from CD4+ cells from healthy, unexposed polish donors, Vaccines (Basel) 8 (4) (2020).

Y.H. Ahn, Y.H. Ko, Diagnostical and therapeutic implications of microRNAs in non-small cell lung cancer, Int. J. Mol. Sci. 21 (22) (2020).

L.L. Zeng, R. Forza, R.A. de Souza, T. Chiapello, J. Seo, A. V. Veloso, MicroRNAs in Lung Cancer Oncogenesis and Tumor Suppression: How It Can Improve the Clinical Practice? Curr. Genomics 21 (5) (2020) 372-381.

A. Tirpe, D. Guli, G.R. Tirpe, A. Nutu, A. Trime, P. Camponeschi, L.A. Pop, J. Nowak-Nieborosz, The New Horizon of Anti-Angiogenic microRNAs in Non-Small Cell Lung Cancer Therapy, Int. J. Mol. Sci. 21 (21) (2020).

C. Hu, K. Hui, X. Jiang, Effects of microRNA regulation on antiangiogenic therapy resistance in non-small cell lung cancer, Biomed. Pharmacother. 131 (2020) 110537.

R. Mirzaei, F. Mahdavi, F. Badrzadeh, S.R. Hosseini-Fard, M. Heidary, A.S. Jeda, T. Mohammadi, T. Moshani, R. Younesifaraboud, H. Keyvany, M. Darvishmotevalli, M.Z. Sani, S. Karampoor, The emerging role of microRNAs as promising therapeutics for SARS-CoV-2 by regulating ACE2 and TMPRSS2 genes affects sensitization and progression of experimental asthma, J. Mol. Cell. Cardiol. 120 (10) (2019) 16876-16887.

A. W.触摸 Button, J. Jitkorn, S. Sangoongruangri, U. Chalidkaew, Circulating levels of Interleukin-6 and -10, but not tumor necrosis factor-alpha, as potential biomarkers of severity and mortality for COVID-19: systematic review with meta-analysis, Clin. Immunol. (2020).

B. Sorger, D. Weismann, B. Schmid, M. Sitter, N. Schlegel, P. Kranke, –

4618 –

386 –

429 –

407 –

399 –

395 –

391 –

387 –

383 –

379 –

375 –

371 –

367 –

363 –

359 –

355 –

351 –

347 –

343 –

339 –

335 –

331 –

327 –

323 –

319 –

315 –

311 –

307 –

303 –

299 –

295 –

291 –

287 –

283 –

279 –

275 –

271 –

267 –

263 –

259 –

255 –

251 –

247 –

243 –

239 –

235 –

231 –

227 –

223 –

219 –

215 –

211 –

207 –

203 –

199 –

195 –

191 –

187 –

183 –

179 –

175 –

171 –

167 –

163 –

159 –

155 –

151 –

147 –

143 –

139 –

135 –

131 –

127 –

123 –

119 –

115 –

111 –

107 –

103 –

99 –

95 –

91 –

87 –

83 –

79 –

75 –

71 –

67 –

63 –

59 –

55 –

51 –

47 –

43 –

39 –

35 –

31 –

27 –

23 –

19 –

15 –

11 –

7 –

3 –

1 –

S. Ahmad et al. Seminars in Cancer Biology 83 (2022) 383–398.
S. Ahmad et al.

Seminars in Cancer Biology 83 (2022) 384–398

384

M. Rokavec, W. Wu, J.L. Luo, IL6-mediated suppression of miR-200c directs
S.M. Eken, T. Christersdottir, G. Winski, T. Sangsuwan, H. Jin, E. Chernogubova,
M.A. Reddy, W. Jin, L. Villeneuve, M. Wang, L. Lanting, I. Todorov, M. Kato,
J. Yu, J. Chen, H. Yang, S. Chen, Z. Wang, Overexpression of miR200a3p
I. Bozgeyik, Therapeutic potential of miRNAs targeting SARS-CoV-2 host cell
F.J. Sheedy, Turning 21: induction of miR-21 as a key switch in the inflammatory
X. Feng, Z. Wang, R. Fillmore, Y. Xi, MiR-200, a new star miRNA in human
D.M. Sun, B.F. Tang, Z.X. Li, H.B. Guo, J.L. Cheng, P.P. Song, X. Zhao, MiR-29c
S. Jafarinejad-Farsangi, M.M. Jazi, F. Rostamzadeh, M. Hadizadeh, High affinity
72
77
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.
82.